Table 1.
Baseline characteristics of the patients in this study (n = 73), separated by virological response
| Parameter | Valuea |
P valuee | |
|---|---|---|---|
| VR (n = 53) | No VR (n = 20) | ||
| Age (yr) | 43 (36–48) | 41 (31–45) | NS |
| No. (%) of males | 39 (79) | 17 (85) | NS |
| No. (%) of patients with HCV coinfectionb | 18 (34) | 8 (40) | NS |
| CD4+ count (cells/mm3) | 355 (243–475) | 63 (16–175) | <0.001 |
| No. (%) of patients in risk group | |||
| IDUc | 19 (35.8) | 11 (55) | NS |
| Sexual risk | 31 (58.5) | 4 (20) | 0.004 |
| Other | 3 (5.7) | 5 (25) | NS |
| No. (%) of patients with stage C disease (according to CDC) | 7 (13.2) | 9 (45) | 0.009 |
| Plasma HIV-1 RNA load (log10 copies/ml) | 4.45 (3.66–4.88) | 4.87 (3.89–5.21) | NS |
| No. (%) of patients with plasma HIV-1 RNA load of <1,000 copies/ml | 9 (17) | 3 (15) | NS |
| ΔVL after MCT (log10 copies/ml)d | −1.32 (−1.03–−1.59) | 0.03 (−0.21–0.23) | <0.001 |
| No. (%) of patients with real MVC monotherapy | 38 (71.7) | 10 (50) | NS |
a
Values other than numbers with percentages are expressed as medians (IQR). VR, virological response.
b
PCR positive for hepatitis C virus.
c
Intravenous drug users.
d
ΔVL, viral load change.
e
NS, P > 0.05.